Dr. Jen Gunter on Women's HRT: What She Has Said About Medication

Who Is Dr. Jen Gunter and Why Do Her Views on HRT Matter?

Dr. Jennifer Gunter is a Canadian-American OB-GYN, pain medicine specialist, and menopause clinician who has spent roughly two decades publicly correcting misinformation about women's health. She is probably best known outside clinical circles for her books "The Vagina Bible" (2019) and "The Menopause Manifesto" (2021), the latter of which spent weeks on major bestseller lists. Her Substack newsletter, "The Vajenda," reaches tens of thousands of paying subscribers and functions as a peer-reviewed-lite translation layer for menopause science.

Her views matter for a specific reason: she does not just advocate for hormone therapy in the abstract. She has stated publicly that she takes it herself, which makes her one of the few physician-public-figures to collapse the distance between clinical recommendation and personal practice.

Her Clinical Background

Gunter completed her OB-GYN residency at the University of Western Ontario and later trained in pain medicine. She practiced at Kaiser Permanente for years and has held faculty appointments allowing her to participate in guideline-adjacent conversations. That background gives her statements about drug selection and dosing a clinical weight that celebrity endorsements lack.

The Platform She Operates On

Unlike influencers who simply share their prescriptions, Gunter systematically cites trial data, names drugs by generic and brand, specifies routes of administration, and links to primary literature. Her 2021 book contains 40 pages of references. When she says she takes a particular formulation, she also explains the pharmacological reasoning.

What Dr. Gunter Has Said About Her Own HRT Use

Gunter has confirmed in multiple public venues, including podcast interviews and her Substack, that she personally uses menopausal hormone therapy. She has been specific enough in these disclosures to be clinically informative without the statements reading as promotional.

Estradiol: Route Matters

In several interviews, Gunter has emphasized that she uses transdermal estradiol rather than oral conjugated equine estrogen (CEE). This is not a trivial distinction. Oral CEE undergoes first-pass hepatic metabolism, which raises sex-hormone-binding globulin, C-reactive protein, and coagulation factors. Transdermal estradiol bypasses the liver entirely.

A 2016 nested case-control study published in the BMJ (N=80,396 women) found that transdermal estradiol was not associated with increased venous thromboembolism risk, while oral estrogen was associated with an odds ratio of approximately 1.58 [1]. Gunter has cited this class of evidence when explaining her personal route preference, making the disclosure pedagogically useful rather than merely personal.

Progesterone: Micronized, Not MPA

Gunter has been explicit that she uses micronized progesterone (brand name Prometrium in the US and Canada) rather than medroxyprogesterone acetate (MPA), the synthetic progestogen used in the original WHI combined-hormone arm.

The WHI combined arm, published in JAMA in 2002, used CEE 0.625 mg plus MPA 2.5 mg and found a hazard ratio for invasive breast cancer of 1.26 after a mean of 5.6 years [2]. Gunter has publicly argued, correctly in line with current guidelines, that conflating MPA data with micronized progesterone data is a scientific error. The E3N French cohort study (N=80,377 women, over 8 years of follow-up) found that estrogen combined with micronized progesterone was not associated with a significantly elevated breast cancer risk compared to estrogen alone [3].

What Dr. Gunter Says About the Women's Health Initiative

Gunter has described the mainstream interpretation of the 2002 WHI findings as one of the most consequential examples of medical misinformation affecting women's health. Her argument is not that the WHI was a bad study. Her argument is that it was systematically misread.

The Timing Hypothesis

The WHI enrolled women with a mean age of 63 years, over a decade past the average age of menopause onset (around 51). The "timing hypothesis," sometimes called the "window of opportunity" hypothesis, holds that starting MHT close to menopause onset produces different cardiovascular and cognitive outcomes than starting it a decade later.

The KRONOS Early Estrogen Prevention Study (KEEPS, N=727, published 2012) and the Danish Osteoporosis Prevention Study (DOPS, N=1,006, 10-year follow-up published in the BMJ in 2012) both support this framing [4][5]. DOPS found a statistically significant reduction in the composite of death, myocardial infarction, and heart failure in women who started hormone therapy early (HR 0.48, 95% CI 0.26 to 0.87, P=0.015) [5].

Gunter has cited the timing hypothesis repeatedly and used it to explain why the WHI findings should not be applied wholesale to a 52-year-old woman presenting in perimenopause.

The NAMS Position

The North American Menopause Society 2022 Position Statement states: "For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture" [6]. Gunter quotes or paraphrases this guidance regularly and her personal position aligns with it closely.

What Dr. Gunter Says About "Bioidentical" Hormones

Gunter is one of the most consistent and vocal critics of the compounded "bioidentical" hormone industry. Her objections are regulatory and pharmacological, not philosophical.

The Regulatory Problem

FDA-approved estradiol and micronized progesterone are, by chemical structure, bioidentical to endogenous human hormones. Gunter's point is that the term "bioidentical" has been hijacked by compounding pharmacies to market untested, unregulated formulations at premium prices.

Compounded hormones fall outside FDA oversight for efficacy and safety testing. The FDA has specifically stated that it has not approved any compounded hormone therapy and that claims of superiority over approved products are not supported by evidence [7]. Gunter has cited the FDA's position and expanded on it in podcast appearances and written pieces.

Saliva Testing

Gunter has also specifically criticized saliva hormone testing, which is frequently sold alongside compounded hormone prescriptions. Serum testing is the validated standard for reproductive hormone assessment. A 2009 review in Clinical Biochemist Reviews found that salivary hormone measurements show high intra-individual variability and do not reliably correlate with serum levels [8]. Gunter has made this point in accessible language for lay audiences.

How Gunter Discusses Testosterone in Women

Gunter's public statements on testosterone for women are notably more cautious than her statements on estrogen and progesterone. She has acknowledged that testosterone may have a role in treating hypoactive sexual desire disorder (HSDD) in postmenopausal women, but she emphasizes that no testosterone product is currently FDA-approved for women in the US.

The Global Consensus Position Statement on the Use of Testosterone Therapy for Women, published in the Journal of Clinical Endocrinology and Metabolism in 2019, supports testosterone therapy for HSDD in postmenopausal women at physiological premenopausal concentrations [9]. Gunter has cited documents in this class while being careful to note the approval gap.

She has not disclosed publicly whether she personally uses testosterone. Any characterization of her testosterone use would be inference and should be labeled as such.

Dr. Gunter's Views on Vaginal Estrogen

Vaginal estrogen is an area where Gunter has been particularly forceful. She has argued that the black-box warning on vaginal estrogen packaging related to systemic estrogen risks is misleading for a low-dose local preparation and has contributed to underuse.

The Evidence Base for Local Estrogen

Vaginal estrogen at low doses (for example, estradiol cream at 2 mcg, conjugated estrogen cream at 0.5 g, or the estradiol vaginal ring releasing 7.5 mcg/day) produces systemic absorption that is generally too low to raise serum estradiol above the normal postmenopausal range. A 2017 ACOG Committee Opinion noted that vaginal estrogen is effective for genitourinary syndrome of menopause (GSM) and that systemic absorption at low doses is minimal [10].

Gunter has cited these data in arguing that even women with a history of hormone-receptor-positive breast cancer may be candidates for low-dose vaginal estrogen after discussion with their oncologist, a position that aligns with guidance from the British Menopause Society.

Her Personal Disclosure

Gunter has mentioned using vaginal estrogen in published essays and interviews, framing it as a straightforward clinical decision given the evidence profile and the symptom burden of GSM.

Dr. Gunter's Critique of the Medical System's Menopause Gap

Beyond her own medication choices, Gunter has made a structural argument: most physicians receive minimal training in menopause medicine, which means patients are frequently either undertreated or frightened away from effective therapy by outdated risk framing.

A 2019 survey published in Menopause (the journal of NAMS) found that only 6.8% of ob-gyn residency programs required a dedicated menopause rotation [11]. Gunter has cited this figure or adjacent data repeatedly.

The HealthRX clinical team has built a triage framework for primary care providers evaluating MHT candidates that maps directly onto the guidance Gunter references: onset of menopause within 10 years, age below 60, absence of estrogen-sensitive malignancy history, absence of unexplained vaginal bleeding, and absence of active thromboembolic disease. Patients who clear all five checkpoints are generally in the favorable benefit-to-risk window described by the NAMS 2022 Position Statement.

What Dr. Gunter Says About Dosing and Monitoring

Gunter has addressed dosing in practical terms in her book and newsletter. She has noted that the goal of HRT is to use the lowest effective dose for symptom control, not to restore reproductive-age hormone levels.

Starting Doses

For transdermal estradiol, common starting doses range from 0.025 mg/day to 0.05 mg/day via patch, with titration based on symptom response rather than serum estradiol targets. Gunter has cited the absence of validated serum estradiol targets for symptom management as one reason why over-reliance on lab monitoring can lead to either undertreatment or unnecessary dose escalation.

The NAMS 2022 Position Statement supports symptom-guided titration over laboratory-guided titration for vasomotor symptoms [6].

Duration of Use

Gunter has argued publicly against the outdated convention of limiting MHT to 5 years. She notes that the NAMS 2022 Position Statement does not specify a maximum duration for appropriate candidates and that the "5-year rule" was derived from WHI data in an older, non-representative population.

She has described continuing her own hormone therapy as a personal medical decision made in consultation with her own physician, rather than a blanket recommendation for all women.

Summary of Key Positions and Drug Choices

| Domain | Gunter's Stated Position | Supporting Evidence She Cites | |---|---|---| | Estrogen route | Transdermal preferred over oral | BMJ 2016 VTE nested case-control [1] | | Progestogen type | Micronized progesterone, not MPA | E3N cohort [3], WHI reanalysis | | Timing of initiation | Within 10 years of menopause or before age 60 | DOPS [5], NAMS 2022 [6] | | Vaginal estrogen | Broadly underused; low systemic absorption | ACOG 2017 [10] | | Compounded hormones | Regulatory concern; no proven superiority | FDA position [7] | | Duration | No fixed maximum for appropriate candidates | NAMS 2022 [6] | | Testosterone | Possible role in HSDD; no US FDA approval for women | Global Consensus 2019 [9] |

Clinical Takeaways for Patients and Providers

Gunter's public advocacy maps onto mainstream evidence-based guideline positions with a high degree of fidelity. She is not an outlier in the menopause medicine community. Her value to patients is translational: she takes guideline language and makes it actionable for people who have been frightened away from effective treatment by news headlines that misread the WHI.

For providers, her body of work highlights two gaps. First, the estrogen formulation gap: many prescribers still default to oral CEE when transdermal estradiol is available and carries a lower thrombotic risk signal. Second, the progestogen gap: MPA remains in widespread use despite micronized progesterone's more favorable breast tissue and cardiovascular profile in observational data.

Women considering MHT should have a structured conversation with a menopause-trained clinician. The Menopause Society (formerly NAMS) maintains a Certified Menopause Practitioner directory at menopause.org, which is the most direct route to clinicians who have passed a competency exam in this specialty.